Novo Nordisk Explores Acquisitions to Strengthen Obesity Portfolio
Reading Time: 2 minutes
The Danish pharmaceutical company Novo Nordisk is already considering its next strategic move despite the recent market launch of the tablet version of Wegovy. CEO Mike Doustdar stated on the sidelines of the JP Morgan Healthcare Conference that the company is actively seeking acquisitions to further strengthen its portfolio in the area of obesity therapies. Open to Large and Small Deals Novo Nordisk is demonstrating flexibility in this regard. According to Doustdar, both smaller acquisitions and very large takeovers are possible, provided that...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
